MCID: ANT011
MIFTS: 47

Antisocial Personality Disorder malady

Category: Mental diseases

Aliases & Classifications for Antisocial Personality Disorder

About this section

Aliases & Descriptions for Antisocial Personality Disorder:

Name: Antisocial Personality Disorder 11 50 39 13 68
Psychopathic Personality Disorder 11
Dissocial Personality Disorder 11
Psychopathic Personality 11
 
Sociopathic Personality 11
Psychopath.personality 11
Asocial Personality 11

Classifications:



External Ids:

Disease Ontology11 DOID:10939
ICD1030 F60.2
ICD9CM32 301.7
MeSH39 D000987
NCIt45 C88413

Summaries for Antisocial Personality Disorder

About this section
Disease Ontology:11 A personality disorder that involves a pervasive pattern of disregard for, and violation of, the rights of others that begins in childhood or early adolescence and continues into adulthood.

MalaCards based summary: Antisocial Personality Disorder, also known as psychopathic personality disorder, is related to personality disorder and schizophrenia. An important gene associated with Antisocial Personality Disorder is MAOA (Monoamine Oxidase A), and among its related pathways are Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics and Biogenic Amine Synthesis. Affiliated tissues include brain, testes and prefrontal cortex, and related mouse phenotypes are taste/olfaction and muscle.

Wikipedia:71 Antisocial personality disorder (ASPD), also known as dissocial personality disorder (DPD) and... more...

Related Diseases for Antisocial Personality Disorder

About this section

Diseases related to Antisocial Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 95)
idRelated DiseaseScoreTop Affiliating Genes
1personality disorder31.1ALDH2, COMT, DRD2, MAOA, SLC6A3, SLC6A4
2schizophrenia29.2ANKK1, COMT, DRD2, MAOA, MAOB, SLC6A3
3conduct disorder11.3
4impulse control disorder10.9
5substance abuse10.4
6cocaine dependence10.3
7alcohol dependence10.2
8neurogenic bladder10.2MAOA, SLC6A4
9adult brainstem astrocytoma10.2MAOA, SLC6A4
10substance dependence10.2
11anodontia10.2SLC6A3, SLC6A4
12kidney pelvis papillary carcinoma10.2MAOA, SLC6A4
13euthyroid sick syndrome10.2DRD2, SLC6A4
14anxiety disorder10.2
15cholestasis-lymphedema syndrome10.2COMT, MAOA
16nephronophthisis 1310.2COMT, SLC6A4
17waardenburg's syndrome10.2DRD2, SLC6A4
18tinea pedis10.2MAOA, SLC6A3, SLC6A4
19intracranial aneurysm10.1ANKK1, DRD2
20borderline personality disorder10.1
21heroin dependence10.1
22rhinoscleroma10.1COMT, DRD2
23scoliosis10.1DRD2, SLC6A3
24ornithosis10.1DRD2, MAOA, SLC6A4
25rectosigmoid junction neoplasm10.1DRD2, SLC6A3
26postencephalitic parkinson disease10.1DRD2, MAOA, SLC6A4
27intracranial cavernous angioma10.1DRD2, SLC6A3, SLC6A4
28splenic abscess10.1DRD2, SLC6A3, SLC6A4
29transmitted_by10.1DRD2, SLC6A3, SLC6A4
30microcephaly 13, primary, autosomal recessive10.1DRD2, MAOA, SLC6A4
31c8 deficiency, type ii10.1COMT, DRD2
32renpenning syndrome10.1COMT, MAOA, SLC6A4
33intrahepatic gall duct cancer10.1COMT, MAOA, SLC6A4
34chronic eosinophilic pneumonia10.1COMT, MAOA, SLC6A4
35multiple personality disorder10.1COMT, MAOA, SLC6A4
36interstitial emphysema10.1DRD2, SLC6A4
37keratosis10.1COMT, MAOA, SLC6A4
38lichen disease10.1COMT, MAOA, SLC6A4
39fechtner syndrome10.1COMT, MAOA, SLC6A4
4018p deletion syndrome10.1ANKK1, DRD2, SLC6A3
41hypoglycemia10.1ANKK1, DRD2, SLC6A4
42autism spectrum disorder10.0COMT, SLC6A3, SLC6A4
43urea cycle disorder10.0COMT, DRD2
44dissociative disorder10.0MAOA, MAOB
45tuberculoid leprosy10.0MAOA, MAOB
46aortic valve disease 210.0COMT, DRD2, SLC6A3
47mucinous adenocarcinoma10.0DRD2, MAOA, SLC6A3, SLC6A4
48hypoglycemic coma10.0MAOA, SLC6A4
49hypereosinophilic syndrome10.0DRD2, MAOA, SLC6A3, SLC6A4
50parotid gland cancer10.0COMT, DRD2, SLC6A3

Comorbidity relations with Antisocial Personality Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Antisocial Personality Disorder:



Diseases related to antisocial personality disorder

Symptoms & Phenotypes for Antisocial Personality Disorder

About this section

MGI Mouse Phenotypes related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053949.2DRD2, SLC6A3, SNAP25
2MP:00053699.1COL25A1, DRD2, SLC6A3, SLC6A4, SNAP25
3MP:00053798.6ALDH2, COMT, DRD2, SLC6A3, SLC6A4, SNAP25
4MP:00053867.0ALDH2, COL25A1, COMT, DRD2, MAOA, MAOB
5MP:00053767.0ALDH2, COL25A1, COMT, DRD2, MAOA, MAOB
6MP:00036316.8ALDH2, COL25A1, COMT, DRD2, MAOA, MAOB

Drugs & Therapeutics for Antisocial Personality Disorder

About this section

Drugs for Antisocial Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Naratriptanapproved, investigationalPhase 415143388-64-1, 121679-13-84440
Synonyms:
121679-13-8
AC-5013
AC1L1I6A
Amerge, Naramig,Naratriptan
BIDD:GT0312
C07792
CHEBI:7478
CHEMBL1278
CID4440
Colatan
D08255
DB00952
InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H
L000432
 
LS-83062
MolPort-005-932-823
N-Methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-Methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide
N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide
N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide
NCGC00181786-01
Naramig
Naramig (TN)
Naratriptan (INN)
Naratriptanum
S1488_Selleck
UNII-QX3KXL1ZA2
naratriptan
naratriptanum
2Vasoconstrictor AgentsPhase 4, Phase 22122
3Neurotransmitter AgentsPhase 418340
4Serotonin AgentsPhase 43156
5
SerotoninPhase 4362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
6Serotonin 5-HT1 Receptor AgonistsPhase 4209
7
EthanolapprovedPhase 2, Phase 3213764-17-5702
Synonyms:
(C6-C9)Alkyl alcohol
02483_FLUKA
02851_FLUKA
02853_FLUKA
02854_FLUKA
02855_FLUKA
02856_FLUKA
02856_SIAL
02857_FLUKA
02857_SIAL
02858_FLUKA
02858_SIAL
02860_FLUKA
02865_FLUKA
02865_SIAL
02870_FLUKA
02870_SIAL
02875_FLUKA
02877_FLUKA
02878_FLUKA
02882_FLUKA
02882_SIAL
02883_FLUKA
02884_FLUKA
02890_FLUKA
02890_SIAL
02891_FLUKA
02891_SIAL
1-Hydroxyethane
100C.NPA
121182-78-3
187380_ALDRICH
187380_SIAL
24102_RIEDEL
24102_SIAL
24103_RIEDEL
24103_SIAL
24105_RIEDEL
24105_SIAL
24106_RIEDEL
24106_SIAL
24194_RIEDEL
24194_SIAL
245119_ALDRICH
245119_SIAL
270741_ALDRICH
270741_SIAL
277649_ALDRICH
277649_SIAL
2858_SIGMA
29221_FLUKA
32205_RIEDEL
32205_SIAL
32221_RIEDEL
32221_SIAL
32294_RIEDEL
32294_SIAL
34870_SIAL
34963_RIEDEL
39278_FLUKA
40210_ALDRICH
40210_RIEDEL
41322_FLUKA
458600_ALDRICH
458600_SIAL
459828_ALDRICH
459828_SIAL
459836_ALDRICH
459836_SIAL
459844_SIAL
48075_SUPELCO
493511_SIAL
493538_ALDRICH
493538_SIAL
493546_ALDRICH
493546_SIAL
64-17-5
676829_SIAL
68475-56-9
71076-86-3
71329-38-9
8000-16-6
8024-45-1
AC1L19TW
AC1Q31MM
AHD 2000
AI3-01706
ALCOHOL 5% IN D5-W
Absolute Alcohol
Absolute Ethanol
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethanol [German]
Aethylalkohol
Alcare Hand Degermer
Alcohol
Alcohol (USP)
Alcohol (ethyl)
Alcohol Anhydrous
Alcohol [USP]
Alcohol anhydrous
Alcohol dehydrated
Alcohol denatured
Alcohol etílico
Alcohol, Absolute
Alcohol, Dehydrated
Alcohol, Diluted
Alcohol, Grain
Alcohol, anhydrous
Alcohol, dehydrated
Alcohol, denatured
Alcohol, diluted
Alcohol, ethyl
Alcohols
Alcohols, C1-3
Alcohols, C30
Alcohols, C6-9
Alcool Ethylique
Alcool Etilico
Alcool ethylique
Alcool etilico
Alcool éthylique
Algrain
Alkohol
Alkohol [German]
Alkoholu Etylowego
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrol PM 4085
Anhydrous alcohol
Anhydrous ethanol
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C00469
C2H5OH
C2H6O
CCRIS 945
CDA 19
CDA 19-200
CHEBI:16236
CHEMBL545
CID702
Caswell No. 426
Caswell No. 430
Colamine
Cologne Spirit
Cologne spirit
Cologne spirits
 
D000431
D00068
DB00898
Dehydrated Ethanol
Dehydrated alcohol
Dehydrated ethanol
Denatured Alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured Ethanol
Denatured alcohol
Denatured ethanol
Desinfektol EL
Diluted Alcohol
Distilled spirits
E2385_SIGMA
E7023_ALDRICH
E7023_SIAL
E7148_ALDRICH
E7148_SIAL
E7517_SIGMA
EINECS 200-578-6
EINECS 270-649-4
EOH
EOX
ETA
Envision Conditioner Pdd 9020
Esumiru WK 88
EtOH
Etanolo
Etanolo [Italian]
Ethanol (9CI)
Ethanol 200 Proof
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol Vapor
Ethanol [JAN]
Ethanol solution
Ethanol, Silent Spirit
Ethanol, undenatured
Ethanolum anhydricum
Ethicap
Ethyl Alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl Alcohol Anhydrous
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl Hydrate
Ethyl Hydroxide
Ethyl alc
Ethyl alcohol
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl hydrate
Ethyl hydroxide
Ethylalcohol
Ethylalcohol [Dutch]
Ethylol
Ethylolamine
Ethyloxy Group
Etylowy alkohol
FEMA No. 2419
FEMA Number 2419
Fermentation alcohol
Glycinol
Grain alcohol
HSDB 531
HSDB 82
HYDROXYETHYL GROUP
Hinetoless
Hydroxyethane
I14-12648
IMS 99
Infinity Pure
Jaysol
Jaysol S
LS-1539
LTBB002977
Lux
Methylated Spirit Mineralised
Methylated spirit
Methylcarbinol
MolPort-001-785-844
Molasses alcohol
NCGC00091458-01
NCI-C03134
NSC 85228
NSC85228
Oxydimethylene Group
Potato alcohol
Punctilious ethyl alcohol
Pyro
QMHAIh@
Reagent Alcohol
Ru-Tuss Expectorant
SDA 3A
SDA 40-2
SDM No. 37
SY Fresh M
Sekundasprit
Silent spirit
Spirit
Spirits of wine
Spiritus vini
Spirt
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
UNII-3K9958V90M
USAF EK-1597
Undenatured Ethanol
WLN: Q2
absolute alcohol
alcohol
alcohol etilico
bmse000297
etanol
ethanol
ethyl alcohol
grain alcohol
nchem.651-comp3c
nchembio.552-comp10
nchembio.94-comp20
spiritus vini
Äthanol
Äthylalkohol
éthanol
8Omega 3 Fatty AcidNutraceuticalPhase 2, Phase 31018
9VasopressinsPhase 2294
10Natriuretic AgentsPhase 21697
11HemostaticsPhase 21443
12CoagulantsPhase 21500
13Arginine VasopressinPhase 2299
14arginineNutraceuticalPhase 2425
15
Guanfacineapproved, investigational5929110-47-23519
Synonyms:
29110-47-2
29110-48-3 (mono-hydrochloride)
AC1L1G4B
BPBio1_000415
BRD-K32830106-003-03-0
BSPBio_000377
C07037
C9H9Cl2N3O
CAS-29110-48-3
CHEMBL862
CID3519
D08031
DB01018
EINECS 249-442-8
Estulic
Estulic (TN)
G1043_SIGMA
GUANFACINE
Guanfacina
Guanfacina [INN-Spanish]
Guanfacine (INN)
Guanfacine Monohydrochloride
Guanfacine [INN:BAN]
Guanfacinum
 
Guanfacinum [INN-Latin]
Intuniv
L000286
L013430
LS-174236
Lon798
Lopac-G-1043
Lopac0_000519
MolPort-003-941-447
N (Aminoiminomethyl)-2,6-dichlorobenzeneacetamide
N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide
NCGC00015469-01
NCGC00015469-02
NCGC00015469-06
NCGC00024950-01
NCGC00024950-02
NCGC00024950-03
Prestwick0_000339
Prestwick1_000339
Prestwick2_000339
Prestwick3_000339
SPBio_002298
SPD 503
Tocris-1030
UNII-30OMY4G3MK
ZINC03872738
16
Norepinephrineapproved69951-41-2439260
Synonyms:
(-)-(R)-Norepinephrine
(-)-Arterenol
(-)-Arterenol free base
(-)-NORADRENALINE
(-)-Noradrenaline
(-)-Norepinephrine
(-)-alpha-(Aminomethyl)protocatechuyl alcohol
(R)-(-)-Norepinephrine
(R)-4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
(R)-4-(2-amino-1-Hydroxyethyl)-1,2-benzenediol
(R)-Noradrenaline
(R)-Norepinephrine
1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)- (9CI)
4-(2-Amino-1-hydroxyethyl)-1,2-benzenediol
4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol
4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol
4899-05-2
51-40-1 (l-tartrate (1:1))
51-41-2
66197-73-7
A7257_SIGMA
AC1L96ZT
ALBB-006229
Adrenor
Aktamin
Arterenol
BRN 4231961
BSPBio_002079
C00547
CHEBI:18357
CHEMBL1437
CID439260
D-(-)-Noradrenaline
D00076
D53D5E3A-2360-4CA9-8031-6C2CD4062FD5
DB00368
DivK1c_000230
EINECS 200-096-6
HMS1920B08
HMS2089E18
HMS2091J08
HMS500L12
IDI1_000230
KBio1_000230
KBio2_001489
KBio2_004057
KBio2_006625
KBio3_001579
KBioGR_000635
KBioSS_001489
L-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
L-3,4-Dihydroxyphenylethanolamine
L-3,4-dihydroxyphenylethanolamine
L-Arterenol
L-Noradrenaline
L-Norepinephrine
L-alpha-(Aminomethyl)-3,4-dihydroxybenzyl alcohol
L-alpha-(aminomethyl)-3,4-dihydroxybenzyl alcohol
L-arterenol
L-noradrenaline
LS-42676
LT03330026
 
LT4
Levarterenol
Levarterenolo
Levarterenolo [DCIT]
Levoarterenol
Levonor
Levonoradrenaline
Levonorepinephrine
Levophed
NCGC00159406-02
NCGC00159406-03
NCGC00159406-04
NCGC00159406-05
NCGC00159406-06
NCGC00159406-07
NCGC00159406-09
NINDS_000230
Nor adrenalin
Nor adrenalin (TN)
Nor-Epirenan
Nor-adrenaline
Noradrenalin
Noradrenalina
Noradrenalina [Italian]
Noradrenaline
Noradrenaline (JP15)
Noradrenalinum
Norartrinal
Noreinefrina
Noreinefrina [INN-Spanish]
Norepinefrina
Norepinephrine
Norepinephrine (INN)
Norepinephrine Noradrenalin
Norepinephrine [INN:JAN]
Norepinephrine l-Tartrate (1:1)
Norepinephrinum
Norepinephrinum [INN-Latin]
Norepirenamine
PDSP1_001111
PDSP2_001095
SGCUT00123
SPBio_001048
SPECTRUM1500436
STK503776
Spectrum2_001064
Spectrum3_000520
Spectrum4_000078
Spectrum5_001068
Spectrum_001009
Sympathin E
UNII-X4W3ENH1CV
bmse000404
l-1-(3,4-Dihydroxyphenyl)-2-aminoethanol
l-2-Amino-1-(3,4-dihydroxyphenyl)ethanol
nchembio.284-comp2
nchembio.64-comp2
nchembio705-1
noradrenaline
norepinefrina
norepinephrine
norepinephrinum
to_000024
17
Yohimbineapproved, vet_approved28146-48-58969
Synonyms:
(+)-Yohimbin
(+)-Yohimbine
(+)-yohimbine
(16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester
146-48-5
17-Hydroxy-yohimbane-16-carboxylic acid methyl ester
17-Hydroxyyohimban-16-carboxylic acid methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylic acid methyl ester
17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester
2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
4-25-00-01237 (Beilstein Handbook Reference)
65-19-0
AC1L1S1D
APHRODINE
Actibine
Aphrodine
Aphrodyne
Aphrosol
BCBcMAP01_000032
BPBio1_000472
BRD-K35586044-001-02-6
BRD-K35586044-003-03-0
BRN 0097276
BSPBio_000428
BSPBio_001236
Baron-X
Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.
Bio1_000455
Bio1_000944
Bio1_001433
Bio2_000458
Bio2_000938
C09256
CHEBI:10093
CHEMBL15245
CID8969
Corynine
D08685
DB01392
Dayto himbin
EINECS 205-672-0
HMS1362N17
HMS1792N17
HMS1990N17
HMS2089G19
I14-13374
IDI1_002213
 
InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s
Johimbin
KBio2_000576
KBio2_003144
KBio2_005712
KBio3_001031
KBio3_001032
KBioGR_000576
KBioSS_000576
LS-162738
Lopac0_001210
MLS000728591
MLS001333983
MolPort-001-794-653
NCGC00025018-05
NCGC00025018-06
NCGC00025018-07
NSC19509
Prestwick0_000584
Prestwick1_000584
Prestwick2_000584
Prestwick3_000584
Quebrachin
Quebrachine
SMP1_000320
SMR000058527
SMR000470778
SPBio_002647
STOCK1N-51304
Thybine
UNII-2Y49VWD90Q
Yocon
Yohimar
Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester
Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester
Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI)
Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI)
Yohimbic acid methyl ester
Yohimbin
Yohimbine
Yohimbine (DCF)
Yohimbol-16alpha-carboxylic acid, methyl ester (6CI)
Yohimex
Yoman
Yovital
methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate
methyl 17alpha-hydroxyyohimban-16alpha-carboxylate
nchembio.188-comp13
nchembio705-2
trans-Quinolizidine yohimbine
18
Dopamineapproved383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
19
Morphineapproved, investigational100757-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
20Dopamine Agents3836
21Lisdexamfetamine Dimesylate98
22Neurotransmitter Uptake Inhibitors3521
23Dopamine Uptake Inhibitors1331
24Autonomic Agents10150
25Adrenergic Agonists3027
26Central Nervous System Stimulants2211
27Adrenergic alpha-Agonists1734
28Adrenergic Agents5352
29Peripheral Nervous System Agents23689
30Detox adjuvant24
31
Silicon1037440-21-34082203
Synonyms:
Si
 
Silica
Silicate
Silicic acid
32Central Nervous System Depressants13403
33Anti-Infective Agents, Local1880
34Anti-Infective Agents22062
35YohimbeNutraceutical28

Interventional clinical trials:

(show all 28)
idNameStatusNCT IDPhase
1Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)CompletedNCT00000388Phase 4
2Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment OrderTerminatedNCT00282165Phase 4
3Effect of Omega-3 Supplementation on Child Behavior ProblemsCompletedNCT02016079Phase 2, Phase 3
4Personality-targeted Interventions for Adolescent Alcohol MisuseCompletedNCT00344474Phase 2, Phase 3
5Vasopressin Effects on Human Social CommunicationUnknown statusNCT01327027Phase 2
6The Impact of Psychopathic Traits on the Efficacy of a Substance Use InterventionCompletedNCT01532934Phase 2
7Working Memory Training in Adults With Substance Abuse and Executive Function Deficits.RecruitingNCT02068261Phase 2
8Antisocial Behavior: Passing From Parent to Child to GrandchildUnknown statusNCT00060788
9Mental Health Related to School Dropout in LuxembourgUnknown statusNCT01354236
10Conduct Disorder in Prison: Search for Prospective and Retrospective Recurring and Contextual ElementsCompletedNCT02493088
11Matching Cognitive Remediation to Cognitive Deficits in Substance-Abusing InmatesCompletedNCT01428349
12Impaired Decision-making in AdolescentsCompletedNCT01253993Early Phase 1
13The Role of Norepinephrine in Emotional ProcessingCompletedNCT00109642
14Early Exposure to Lead and Adult Antisocial OutcomesCompletedNCT00285610
15To Evaluate the Safety and Metabolic Profile of Vyvanse for the Treatment of ADHD in Euthymic Adults With Bipolar I/II DisorderCompletedNCT01263548
16Psychological Mechanisms of Behavioral DysregulationCompletedNCT00352456
17Study of Children at Risk for Disruptive Behavior DisordersCompletedNCT00001233
18Justice-Involved Veterans and Moral Reconation TherapyRecruitingNCT02524171
19Multisystemic Therapy-Emerging Adults TrialRecruitingNCT02922335
20The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive BehaviorRecruitingNCT02427672
21ADHD: Gaps Between Patients With Alcohol-dependence and Impact on RelapseRecruitingNCT02364817
22Mentalization-based Training for Adolescents With Conduct Disorder (MBT-CD)RecruitingNCT02988453
23Personality Pathology and Cerebral Processing in Eating DisordersRecruitingNCT02980120
24The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive BehaviorActive, not recruitingNCT02674516
25Multisite Prevention of Conduct Problems (Fast Track)Active, not recruitingNCT01653535
26Psychobiological Effects of Meditation on Offenders With PsychopathyNot yet recruitingNCT02894203
27Multisystemic Therapy-Emerging Adults (MST-EA) for Substance AbuseNot yet recruitingNCT03035877
28Role of Oxytocin in Telling and Detecting LiesWithdrawnNCT02361177Early Phase 1

Search NIH Clinical Center for Antisocial Personality Disorder


Cochrane evidence based reviews: antisocial personality disorder

Genetic Tests for Antisocial Personality Disorder

About this section

Anatomical Context for Antisocial Personality Disorder

About this section

MalaCards organs/tissues related to Antisocial Personality Disorder:

36
Brain, Testes, Prefrontal cortex, Cortex, Eye

Publications for Antisocial Personality Disorder

About this section

Articles related to Antisocial Personality Disorder:

(show top 50)    (show all 364)
idTitleAuthorsYear
1
Did you get any help? A post-hoc secondary analysis of a randomized controlled trial of psychoeducation for patients with antisocial personality disorder in outpatient substance abuse treatment programs. (28068951)
2017
2
Neurocognitive Deficits Associated with Antisocial Personality Disorder in Non-treatment-seeking Young Adults. (27236178)
2016
3
Genome-wide association study of antisocial personality disorder. (27598967)
2016
4
Modulatory effects of psychopathy on Wisconsin Card Sorting Test performance in male offenders with Antisocial Personality Disorder. (26708441)
2016
5
Psychopathy, Antisocial Personality Disorder, and Reconviction in an Australian Sample of Forensic Patients. (27288398)
2016
6
Facial emotion perception impairments in schizophrenia patients with comorbid antisocial personality disorder. (26778631)
2016
7
Association of ventral striatum monoamine oxidase-A binding and functional connectivity in antisocial personality disorder with high impulsivity: A positron emission tomography and functional magnetic resonance imaging study. (26908392)
2016
8
Experiential avoidance, empathy, and anger-related attitudesin antisocial personality disorder. (28081330)
2016
9
Evidence for an agitated-aggressive syndrome in early-onset psychosis correlated with antisocial personality disorder, forensic history, and substance use disorder. (27117676)
2016
10
Impulsive lifestyle counseling to prevent dropout from treatment for substance use disorders in people with antisocial personality disorder: A randomized study. (26882500)
2016
11
Individual and Network Correlates of Antisocial Personality Disorder Among Rural Nonmedical Prescription Opioid Users. (27171488)
2016
12
Neural Substrates of Antisocial Personality Disorder: Current State and Future Directions. (27776462)
2016
13
Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. (27839828)
2016
14
An Adverse Family Environment During Adolescence Predicts Marijuana Use and Antisocial Personality Disorder in Adulthood. (27034610)
2016
15
Heightened early-attentional stimulus orienting and impulsive action in men with antisocial personality disorder. (27662886)
2016
16
Examining the DSM-5 Alternative Personality Disorder Model Operationalization of Antisocial Personality Disorder and Psychopathy in a Male Correctional Sample. (26914324)
2016
17
Comorbid trajectories of substance use as predictors of Antisocial Personality Disorder, Major Depressive Episode, and Generalized Anxiety Disorder. (27344118)
2016
18
Aberrant functional brain connectome in people with antisocial personality disorder. (27257047)
2016
19
A randomised controlled trial of mentalization-based treatment versus structured clinical management for patients with comorbid borderline personality disorder and antisocial personality disorder. (27577562)
2016
20
Reduced cortical thickness and increased surface area in antisocial personality disorder. (27600947)
2016
21
Offenders With Antisocial Personality Disorder Display More Impairments in Mentalizing. (27064853)
2016
22
Disrupted functional connectome in antisocial personality disorder. (27541949)
2016
23
Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder. (26250442)
2015
24
Lifetime trauma victimization and PTSD in relation to psychopathy and antisocial personality disorder in a sample of incarcerated women and men. (26062658)
2015
25
Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [(11)C] Harmine Positron Emission Tomography Study. (26081301)
2015
26
Psycho-education for substance use and antisocial personality disorder: a randomized trial. (26573140)
2015
27
Do people with borderline personality disorder complicated by antisocial personality disorder benefit from the STEPPS treatment program? (26671625)
2015
28
The Natural History of Antisocial Personality Disorder. (26175389)
2015
29
Gender differences in the clinical characteristics and psychiatric comorbidity in patients with antisocial personality disorder. (26296756)
2015
30
The relationship between five-factor model and diagnostic and statistical manual of mental disorder-fifth edition personality traits on patients with antisocial personality disorder. (26487876)
2015
31
Mindfulness moderates the relationship between aggression and Antisocial Personality Disorder traits: Preliminary investigation with an offender sample. (26350275)
2015
32
Co-occurring mental illness, substance use disorders, and antisocial personality disorder among clients of forensic mental health services. (25799303)
2015
33
A longitudinal twin study of borderline and antisocial personality disorder traits in early to middle adulthood. (26050739)
2015
34
They're Really PD Today": An Exploration of Mental Health Nursing Students' Perceptions of Developing a Therapeutic Relationship With Patients With a Diagnosis of Antisocial Personality Disorder. (26169569)
2015
35
Effects of Intranasal Oxytocin on Aggressive Responding in Antisocial Personality Disorder. (27022201)
2015
36
Epidemiology, Comorbidity, and Behavioral Genetics of Antisocial Personality Disorder and Psychopathy. (26594067)
2015
37
Monoamine oxidase A gene promoter methylation and transcriptional downregulation in an offender population with antisocial personality disorder. (25497297)
2015
38
Antisocial Personality Disorder and Pathological Narcissism in Prolonged Conflicts and Wars of the 21st Century. (26456397)
2015
39
Examining the Role of Antisocial Personality Disorder in Intimate Partner Violence Among Substance Use Disorder Treatment Seekers With Clinically Significant Trauma Histories. (26084544)
2015
40
Associations between Antisocial Personality Disorder and Sex on Discounting Rates. (25364042)
2014
41
The validity and clinical utility of structured diagnoses of antisocial personality disorder with forensic patients. (24511901)
2014
42
Comparing the Utility of DSM-5 Section II and III Antisocial Personality Disorder Diagnostic Approaches for Capturing Psychopathic Traits. (25364943)
2014
43
Lower anterior cingulate volume in seriously violent men with antisocial personality disorder or schizophrenia and a history of childhood abuse. (24234836)
2014
44
Examining the associations between DSM-5 section III antisocial personality disorder traits and psychopathy in community and university samples. (24689766)
2014
45
Prevalence of antisocial personality disorder among Chinese individuals receiving treatment for heroin dependence: a meta-analysis. (25477719)
2014
46
DSM-IV antisocial personality disorder and conduct disorder: evidence for taxonic structures among individuals with and without substance use disorders in the general population. (24766762)
2014
47
The social construction of violence among Northern Plains tribal members with antisocial personality disorder and alcohol use disorder. (24045407)
2014
48
Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. (24698103)
2014
49
Physiological correlates of psychopathy, antisocial personality disorder, habitual aggression, and violence. (25129139)
2014
50
Changes in low-frequency fluctuations in patients with antisocial personality disorder revealed by resting-state functional MRI. (24598769)
2014

Variations for Antisocial Personality Disorder

About this section

Expression for genes affiliated with Antisocial Personality Disorder

About this section
Search GEO for disease gene expression data for Antisocial Personality Disorder.

Pathways for genes affiliated with Antisocial Personality Disorder

About this section

Pathways related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

(show all 19)
idSuper pathwaysScoreTop Affiliating Genes
19.8MAOA, SLC6A4
2
Show member pathways
9.7COMT, MAOA
3
Show member pathways
9.6COMT, SLC6A4
4
Show member pathways
9.5MAOA, SLC6A3, SLC6A4
5
Show member pathways
9.4MAOA, MAOB
69.3MAOB, SLC6A3
79.2MAOA, SLC6A4, SNAP25
89.0MAOA, MAOB, SLC6A4
9
Show member pathways
8.8ALDH2, MAOA, MAOB
10
Show member pathways
8.8ALDH2, MAOA, MAOB
11
Show member pathways
8.8ALDH2, MAOA, MAOB
12
Show member pathways
8.8ALDH2, MAOA, MAOB
138.8COMT, MAOA, MAOB
14
Show member pathways
8.8COMT, MAOA, MAOB
15
Show member pathways
8.7DRD2, MAOA, MAOB, SLC6A3
16
Show member pathways
8.4ALDH2, COMT, MAOA, SLC6A3, SLC6A4
17
Show member pathways
8.3ALDH2, COMT, MAOA, MAOB
18
Show member pathways
8.1COMT, DRD2, MAOA, MAOB, SLC6A3
19
Show member pathways
7.8ALDH2, COMT, MAOA, SLC6A3, SLC6A4, SNAP25

GO Terms for genes affiliated with Antisocial Personality Disorder

About this section

Cellular components related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1axonGO:00304248.6COMT, DRD2, SLC6A3, SNAP25

Biological processes related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1adenohypophysis developmentGO:002198410.5DRD2, SLC6A3
2positive regulation of multicellular organism growthGO:004001810.5DRD2, SLC6A3
3ammonium transmembrane transportGO:007248810.5SLC6A3, SLC6A4
4prepulse inhibitionGO:006013410.5DRD2, SLC6A3
5response to cocaineGO:004222010.4DRD2, SLC6A3
6dopamine uptake involved in synaptic transmissionGO:005158310.4SLC6A3, SLC6A4
7monoamine transportGO:001584410.4SLC6A3, SLC6A4
8neurotransmitter biosynthetic processGO:004213610.4SLC6A3, SLC6A4
9neurotransmitter transportGO:000683610.4SLC6A3, SLC6A4
10catecholamine metabolic processGO:000658410.3COMT, MAOA
11response to iron ionGO:001003910.3DRD2, SLC6A3
12dopamine metabolic processGO:004241710.3COMT, DRD2
13response to nicotineGO:003509410.3DRD2, SLC6A3
14associative learningGO:000830610.2DRD2, SNAP25
15locomotory behaviorGO:00076269.8DRD2, SLC6A3, SNAP25
16response to ethanolGO:00454719.5DRD2, MAOB, SLC6A3
17neurotransmitter catabolic processGO:00421359.5COMT, MAOA, MAOB
18dopamine catabolic processGO:00424209.1COMT, MAOA, MAOB, SLC6A3
19response to toxic substanceGO:00096369.0DRD2, MAOB, SLC6A4
20response to drugGO:00424938.7COMT, DRD2, MAOB, SLC6A3, SLC6A4

Molecular functions related to Antisocial Personality Disorder according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine bindingGO:003524010.2DRD2, SLC6A3
2dopamine:sodium symporter activityGO:000533010.2SLC6A3, SLC6A4
3monoamine transmembrane transporter activityGO:000850410.2SLC6A3, SLC6A4
4neurotransmitter:sodium symporter activityGO:000532810.1SLC6A3, SLC6A4
5primary amine oxidase activityGO:00081319.7MAOA, MAOB
6syntaxin-1 bindingGO:00170759.5SLC6A4, SNAP25

Sources for Antisocial Personality Disorder

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet